SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

Wayrilz

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2 (completed per local data)
Time to market
Unknown, local data shows only completed Phase 2 studies (ITP and atopic dermatitis); no FDA filing or approval records are present locally and external verification was unavailable, so time to potential approval/commercialization cannot be estimated.
Why 3/10
No hard, dated catalyst (PDUFA, approval decision, or pivotal readout) for this drug could be verified in the next ~12 months, the local FDA/catalyst datasets contain no record for it and the external web was unavailable all session, and it is one program inside a mega-cap, so even a positive event would be a modest single-stock move.
Actionable Insight NEUTRAL

Watch Sanofi's 6-K filings and corporate updates for any FDA/EMA filing announcement or late-stage readout for rilzabrutinib (ITP and atopic-dermatitis Phase 2 studies are complete); with none verifiable, there is no dated binary to trade today.

Price Chart

Loading chart...

Executive Summary

"Wayrilz" is almost certainly Sanofi's (SNY, ADR ~$43.08 as of the 2026-07-31 close) oral BTK inhibitor rilzabrutinib, an asset Sanofi inherited via its Principia Biopharma acquisition, the name fingerprint and the SNY filing hint point there, and local trial data confirm rilzabrutinib is a Sanofi/Principia program with two completed Phase 2 studies (ITP, atopic dermatitis). Net investor read: neutral, a plausible late-stage program at a diversified mega-cap, but with no verifiable dated catalyst and an unconfirmed identity this session.

How It Works

Rilzabrutinib is an oral (pill) drug that blocks an immune-cell enzyme called Bruton's tyrosine kinase (BTK). B cells and certain white blood cells need BTK to produce the antibodies and inflammatory signals that drive diseases like ITP (where the immune system mistakenly destroys blood platelets, raising bleeding risk) and allergic skin inflammation in atopic dermatitis. Blocking BTK is intended to dampen that immune attack. (Identity caveat: "Wayrilz" as the brand name could not be web-verified this session.)

Trial Status

Two Sanofi-sponsored rilzabrutinib Phase 2 trials are recorded as COMPLETED with results posted: NCT03395210 in immune thrombocytopenia (ITP, 86 enrolled, sponsor "Principia Biopharma, a Sanofi Company", primary completion Jan 2023) and NCT05018806 in moderate-to-severe atopic dermatitis (124 enrolled, completion June 2023). No Phase 3, FDA approval, or other regulatory action records for rilzabrutinib exist in the local datasets searched this session.

The Two-Sided Case

▲ Bull Case4
Developer verified: ticker SNY resolves to Sanofi (CIK 0001121404, ADR), a large diversified pharma with the capital and commercial infrastructure to develop and launch the drug.
Internal ClinicalTrials.gov records show two Sanofi/Principia rilzabrutinib Phase 2 trials (ITP, atopic dermatitis) COMPLETED with results posted, indicating the program advanced beyond early stage.
Sanofi ADR analyst snapshot is constructive: consensus (29 ratings, period 2026-07-01) has 16 buy/strong-buy vs 13 hold/sell, and the 9-analyst price-target snapshot shows mean $54.61 vs ~$43.08 close, roughly 26.5% implied upside per the local data.
Even if Wayrilz/rilzabrutinib fails or stalls, it is one program at a mega-cap with approved products (e.g., Sarclisa Escena SC approval July 2026 recorded in FDA data), limiting idiosyncratic downside.
▼ Bear Case4
No FDA action records (approval, CRL, or safety labeling) and no catalyst/outcome records for rilzabrutinib exist in the local datasets, meaning regulatory status and any upcoming PDUFA/readout are unknown, there is no dated binary to trade.
Analyst sentiment cooled through late 2025: local records show downgrades by UBS (Buy→Neutral, Jan 2026), Barclays (Overweight→Equal-Weight, Jan 2026), Guggenheim (Buy→Neutral, Dec 2025) and JP Morgan (Overweight→Neutral, Dec 2025).
BTK inhibitors are a crowded, established class (ibrutinib, acalabrutinib, zanubrutinib, pirtobrutinib family), so any new entrant faces strong competition and pricing pressure.
Concentration is low: at a company Sanofi's size, even a successful approval of one oral drug would be a small percentage driver of the ADR.

Upcoming Catalysts

  • None verifiable from local data, no PDUFA, approval decision, or pivotal readout for rilzabrutinib appears in the FDA/catalyst datasets.
  • Watch Sanofi's periodic SEC 6-K filings (e.g., filed 2026-07-30 and 2026-07-27) and corporate updates for any regulatory submission, approval, or late-stage readout announcement for rilzabrutinib.
  • Re-run web research once external search recovers to confirm the 'Wayrilz' brand name, ITP (Phase 3 LUNA program) and chronic spontaneous urticaria readout timing, and any FDA action.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov4 accessdata.fda.gov5 accessdata.fda.gov